- Pendopharm and Ascendis Pharma announced that CDA-AMC has recommended reimbursement with conditions for Yorvipath (palopegteriparatide) for eligible adults with chronic hypoparathyroidism inadequately controlled with conventional therapy.
- The recommendation marks an important step toward public reimbursement. Yorvipath, a parathyroid hormone (PTH) replacement therapy, was authorized by Health Canada in January 2026 for chronic hypoparathyroidism in adults.
- CDA-AMC’s review considered Phase 3 PaTHway trial evidence evaluating palopegteriparatide in adults with chronic hypoparathyroidism, where conventional therapy generally includes oral calcium and active vitamin D.
- Final listing decisions will now be made independently by participating federal, provincial and territorial drug plans, determining potential public access to Yorvipath for eligible patients across Canada.
Takeaways:
CDA-AMC’s conditional reimbursement recommendation for Yorvipath moves the therapy closer to public funding in Canada for adults with chronic hypoparathyroidism who are not well controlled on standard calcium and vitamin D supplements. Final coverage will depend on separate decisions by federal, provincial and territorial drug plans, but the positive review strengthens the case for broader access and could shift some patients from long-term supplement regimens to a PTH replacement approach if price and listing terms are agreed.
Source: Globenewswire
